The final CatBoost model included, among the top 15 variables to predict hidden malignancy within the first two years following VTE diagnosis, patient’s demographic data (age and gender), vital signs on admission (systolic blood pressure and heart rate), comorbidities (weight and chronic lung disease), laboratory parameters on admission (D-dimer, alanine aminotransferase, hemoglobin, serum creatinine, cholesterol, platelets, triglycerides, and leukocyte count), and previous VTE. The gene discussed is GPT; the disease is chronic lung disease.